Successful Desensitization of a Patient with Rituximab Hypersensitivity

Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ataca, Pinar, Atilla, Erden, Kendir, Resat, Bavbek, Sevim, Ozcan, Muhit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320878/
https://www.ncbi.nlm.nih.gov/pubmed/25685566
http://dx.doi.org/10.1155/2015/524507
_version_ 1782356205411237888
author Ataca, Pinar
Atilla, Erden
Kendir, Resat
Bavbek, Sevim
Ozcan, Muhit
author_facet Ataca, Pinar
Atilla, Erden
Kendir, Resat
Bavbek, Sevim
Ozcan, Muhit
author_sort Ataca, Pinar
collection PubMed
description Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization. In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered.
format Online
Article
Text
id pubmed-4320878
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-43208782015-02-15 Successful Desensitization of a Patient with Rituximab Hypersensitivity Ataca, Pinar Atilla, Erden Kendir, Resat Bavbek, Sevim Ozcan, Muhit Case Reports Immunol Case Report Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization. In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered. Hindawi Publishing Corporation 2015 2015-01-20 /pmc/articles/PMC4320878/ /pubmed/25685566 http://dx.doi.org/10.1155/2015/524507 Text en Copyright © 2015 Pinar Ataca et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Ataca, Pinar
Atilla, Erden
Kendir, Resat
Bavbek, Sevim
Ozcan, Muhit
Successful Desensitization of a Patient with Rituximab Hypersensitivity
title Successful Desensitization of a Patient with Rituximab Hypersensitivity
title_full Successful Desensitization of a Patient with Rituximab Hypersensitivity
title_fullStr Successful Desensitization of a Patient with Rituximab Hypersensitivity
title_full_unstemmed Successful Desensitization of a Patient with Rituximab Hypersensitivity
title_short Successful Desensitization of a Patient with Rituximab Hypersensitivity
title_sort successful desensitization of a patient with rituximab hypersensitivity
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320878/
https://www.ncbi.nlm.nih.gov/pubmed/25685566
http://dx.doi.org/10.1155/2015/524507
work_keys_str_mv AT atacapinar successfuldesensitizationofapatientwithrituximabhypersensitivity
AT atillaerden successfuldesensitizationofapatientwithrituximabhypersensitivity
AT kendirresat successfuldesensitizationofapatientwithrituximabhypersensitivity
AT bavbeksevim successfuldesensitizationofapatientwithrituximabhypersensitivity
AT ozcanmuhit successfuldesensitizationofapatientwithrituximabhypersensitivity

Ejemplares similares